Liraglutide, a commonly used GLP-1R agonist in clinical practice, is also being investigated to treat NAFLD, a condition that is common in those with obesity and T2DM and is increasing in incidence and for which drug development is challenging and few effective therapies are available [4, 5]. The gene discussed is GLP1R; the disease is Obesity.